Zacks Research Has Optimistic Outlook of CORT Q2 Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Stock analysts at Zacks Research raised their Q2 2025 EPS estimates for shares of Corcept Therapeutics in a research report issued to clients and investors on Wednesday, March 19th. Zacks Research analyst K. Das now expects that the biotechnology company will post earnings per share of $0.37 for the quarter, up from their previous forecast of $0.34. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q3 2025 earnings at $0.47 EPS, FY2025 earnings at $1.64 EPS, Q2 2026 earnings at $0.67 EPS, Q3 2026 earnings at $0.82 EPS, Q4 2026 earnings at $0.89 EPS, FY2026 earnings at $2.83 EPS and FY2027 earnings at $3.81 EPS.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.11). The company had revenue of $181.89 million for the quarter, compared to analysts’ expectations of $200.12 million. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%.

Other analysts have also recently issued research reports about the stock. Piper Sandler raised their price objective on shares of Corcept Therapeutics from $67.00 to $78.00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. HC Wainwright restated a “buy” rating and set a $115.00 price objective on shares of Corcept Therapeutics in a research report on Thursday, February 27th. Canaccord Genuity Group raised their price objective on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the company a “buy” rating in a research report on Thursday, January 30th. Finally, StockNews.com downgraded shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, February 28th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $99.75.

Corcept Therapeutics Stock Performance

Corcept Therapeutics stock opened at $58.66 on Friday. The firm’s fifty day moving average price is $61.49 and its 200-day moving average price is $53.68. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.70. The stock has a market cap of $6.19 billion, a P/E ratio of 46.56 and a beta of 0.61. Corcept Therapeutics has a fifty-two week low of $20.84 and a fifty-two week high of $75.00.

Insiders Place Their Bets

In other news, insider Sean Maduck sold 20,000 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $50.39, for a total transaction of $1,007,800.00. Following the completion of the transaction, the insider now directly owns 85,318 shares of the company’s stock, valued at approximately $4,299,174.02. This represents a 18.99 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Joseph K. Belanoff sold 2,924 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $60.91, for a total transaction of $178,100.84. Following the transaction, the chief executive officer now directly owns 3,019,411 shares of the company’s stock, valued at approximately $183,912,324.01. This trade represents a 0.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 45,627 shares of company stock valued at $2,557,674 over the last three months. Insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Corcept Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of CORT. Kestra Investment Management LLC purchased a new position in shares of Corcept Therapeutics during the fourth quarter valued at about $27,000. Canada Pension Plan Investment Board purchased a new position in shares of Corcept Therapeutics during the fourth quarter valued at about $40,000. National Bank of Canada FI purchased a new position in shares of Corcept Therapeutics during the fourth quarter valued at about $42,000. USA Financial Formulas purchased a new position in shares of Corcept Therapeutics during the fourth quarter valued at about $54,000. Finally, Newbridge Financial Services Group Inc. purchased a new position in shares of Corcept Therapeutics during the fourth quarter valued at about $58,000. 93.61% of the stock is owned by institutional investors.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.